The Prostate Health Index (PHI) from Beckman Coulter Diagnostics, Brea, Calif, reduces the need for men with elevated PSA levels to undergo biopsy to achieve an accurate diagnosis. The non-invasive blood test is three times more specific in detecting prostate cancer than prostate-specific antigen (PSA), a naturally occurring protein whose levels are typically elevated when cancer is present. Utilizing three PSA markers, including PSA, freePSA, and p2PSA, the PHI test avoids the risk of false positives associated with PSA testing due to benign enlargement or inflammation of the prostate. According to the company, a multi-center clinical study found a 31% reduction in unnecessary biopsies as a result of implementing the PHI test. For more information, visit Beckman Coulter Diagnostics.